首页 > 最新文献

Revista espanola de medicina nuclear e imagen molecular最新文献

英文 中文
99mTc-FAPI uptake in a rare case of metastatic urachal carcinoma 一例罕见的转移性泌尿道癌中的 99mTc-FAPI 摄取。
Pub Date : 2024-09-01 DOI: 10.1016/j.remnie.2024.500019
{"title":"99mTc-FAPI uptake in a rare case of metastatic urachal carcinoma","authors":"","doi":"10.1016/j.remnie.2024.500019","DOIUrl":"10.1016/j.remnie.2024.500019","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500019"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
99mTc-MDP bone scintigraphy and 18F-FDG PET/CT findings of osteosarcoma with widespread calcified extraskeletal metastases 骨肉瘤伴广泛钙化骨外转移的 99mTc-MDP 骨闪烁成像和 18F-FDG PET/CT 发现。
Pub Date : 2024-09-01 DOI: 10.1016/j.remnie.2024.500022
{"title":"99mTc-MDP bone scintigraphy and 18F-FDG PET/CT findings of osteosarcoma with widespread calcified extraskeletal metastases","authors":"","doi":"10.1016/j.remnie.2024.500022","DOIUrl":"10.1016/j.remnie.2024.500022","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500022"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incomplete resection in a rare case of bladder paraganglioma revealed by diuretic 123I-MIBG SPECT/CT scan 利尿剂 123I-MIBG SPECT/CT 扫描显示一例罕见的膀胱副神经节瘤未完全切除。
Pub Date : 2024-09-01 DOI: 10.1016/j.remnie.2024.500018
{"title":"Incomplete resection in a rare case of bladder paraganglioma revealed by diuretic 123I-MIBG SPECT/CT scan","authors":"","doi":"10.1016/j.remnie.2024.500018","DOIUrl":"10.1016/j.remnie.2024.500018","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500018"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Popliteal pseudoaneurysm of fungal etiology 真菌引起的腘窝假性动脉瘤。
Pub Date : 2024-09-01 DOI: 10.1016/j.remnie.2024.500025
{"title":"Popliteal pseudoaneurysm of fungal etiology","authors":"","doi":"10.1016/j.remnie.2024.500025","DOIUrl":"10.1016/j.remnie.2024.500025","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500025"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141187074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The value of PET/CT radiomic texture analysis of primary mass and mediastinal lymph node on survival in patients with non-small cell lung cancer PET/CT 对非小细胞肺癌患者原发肿块和纵隔淋巴结的放射纹理分析对生存期的影响
Pub Date : 2024-09-01 DOI: 10.1016/j.remnie.2024.500027
N. Agüloğlu , A. Aksu , D.S. Unat , Ö. Selim Unat

Objective

This study was designed to determine the potential prognostic value of radiomic texture analysis and metabolic-volumetric parameters obtained from positron emission tomography (PET) in primary mass and metastatic hilar/mediastinal lymph nodes in stage 2–3 non-small cell lung cancer (NSCLC).

Methods

Images of patients diagnosed with stage 2–3 NSCLC who underwent 18F-FDG PET/CT imaging for staging up to 4 weeks before the start of treatment were evaluated using LIFEx software. Volume of interest (VOI) was generated from the primary tumor and metastatic lymph node separately, and volumetric and textural features were obtained from these VOIs. The relationship between the parameters obtained from PET of primary mass and the metastatic hilar/mediastinal lymph nodes with overall survival (OS) and progression-free survival (PFS) was analyzed.

Results

When radiomic features, gender and stage obtained from lymph nodes were evaluated by Cox regression analysis; GLCM_correlation (p: 0.033, HR: 4,559, 1.660–12.521, 95% CI), gender and stage were determined as prognostic factors predicting OS. In predicting PFS; stage, smoking and lymph node MTV (p: 0.033, HR: 1.008, 1.001–1.016, 95% CI) were determined as prognostic factors. However, the radiomic feature of the primary tumor could not show a significant relationship with either OS or PFS.

Conclusions

In a retrospective cohort of NSCLC patients with Stage 2 and 3 disease, volumetric and radiomic texture characteristics obtained from metastatic lymph nodes were associated with PFS and OS. Tumor heterogeneity, defined by radiomic texture features of 18 F-FDG PET/CT images, may provide complementary prognostic value in NSCLC.

研究目的本研究旨在确定正电子发射断层扫描(PET)对 2-3 期非小细胞肺癌(NSCLC)原发肿块和转移性肝门/纵隔淋巴结的放射纹理分析和代谢容积参数的潜在预后价值:使用 LIFEx 软件对确诊为 2-3 期 NSCLC 患者的图像进行评估,这些患者在开始治疗前 4 周接受了 18 F-FDG PET/CT 分期成像。分别从原发肿瘤和转移淋巴结生成感兴趣体积(VOI),并从这些 VOI 获取体积和纹理特征。分析了原发肿块和转移性腹股沟/纵隔淋巴结 PET 获得的参数与总生存期(OS)和无进展生存期(PFS)之间的关系:通过 Cox 回归分析评估了淋巴结的放射学特征、性别和分期;GLCM_相关性(P:0.033,HR:4 559,1.660-12.521,95% CI)、性别和分期被确定为预测 OS 的预后因素。在预测 PFS 方面,分期、吸烟和淋巴结 MTV(P:0.033,HR:1.008,1.001-1.016,95% CI)被确定为预后因素。然而,原发肿瘤的放射学特征与OS或PFS均无显著关系:结论:在一项对2期和3期NSCLC患者的回顾性队列研究中,从转移淋巴结获得的肿瘤体积和放射学纹理特征与PFS和OS有关。根据18 F-FDG PET/CT图像的放射纹理特征定义的肿瘤异质性可能对NSCLC的预后具有补充价值。
{"title":"The value of PET/CT radiomic texture analysis of primary mass and mediastinal lymph node on survival in patients with non-small cell lung cancer","authors":"N. Agüloğlu ,&nbsp;A. Aksu ,&nbsp;D.S. Unat ,&nbsp;Ö. Selim Unat","doi":"10.1016/j.remnie.2024.500027","DOIUrl":"10.1016/j.remnie.2024.500027","url":null,"abstract":"<div><h3>Objective</h3><p>This study was designed to determine the potential prognostic value of radiomic texture analysis and metabolic-volumetric parameters obtained from positron emission tomography (PET) in primary mass and metastatic hilar/mediastinal lymph nodes in stage 2–3 non-small cell lung cancer (NSCLC).</p></div><div><h3>Methods</h3><p>Images of patients diagnosed with stage 2–3 NSCLC who underwent 18F-FDG PET/CT imaging for staging up to 4 weeks before the start of treatment were evaluated using LIFEx software. Volume of interest (VOI) was generated from the primary tumor and metastatic lymph node separately, and volumetric and textural features were obtained from these VOIs. The relationship between the parameters obtained from PET of primary mass and the metastatic hilar/mediastinal lymph nodes with overall survival (OS) and progression-free survival (PFS) was analyzed.</p></div><div><h3>Results</h3><p>When radiomic features, gender and stage obtained from lymph nodes were evaluated by Cox regression analysis; GLCM_correlation (p: 0.033, HR: 4,559, 1.660–12.521, 95% CI), gender and stage were determined as prognostic factors predicting OS. In predicting PFS; stage, smoking and lymph node MTV (p: 0.033, HR: 1.008, 1.001–1.016, 95% CI) were determined as prognostic factors. However, the radiomic feature of the primary tumor could not show a significant relationship with either OS or PFS.</p></div><div><h3>Conclusions</h3><p>In a retrospective cohort of NSCLC patients with Stage 2 and 3 disease, volumetric and radiomic texture characteristics obtained from metastatic lymph nodes were associated with PFS and OS. Tumor heterogeneity, defined by radiomic texture features of 18 F-FDG PET/CT images, may provide complementary prognostic value in NSCLC.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500027"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of intraoperative imaging with a portable gamma camera with extemporaneous histology in minimally invasive surgery for primary hyperparathyroidism 原发性甲状旁腺功能亢进症微创手术中使用便携式伽马相机进行术中成像与即刻组织学检查的比较。
Pub Date : 2024-09-01 DOI: 10.1016/j.remnie.2024.500030
Abreu P. , Guallart F. , Siscar C. , Navas M.A. , Casas L. , Montenegro F.

Introduction

The curative treatment of primary hyperparathyroidism (PPH) is surgical and today it can be performed by minimally invasive surgery (MIS) and also be radioguided (RG) if a radiopharmaceutical with affinity for the parathyroid tissue that can be detected with gamma-detector probes or with a portable gamma camera (PGC) is injected.

Aim

The objective is to assess whether intraoperative scintigraphy (GGio) with PGC can replace intraoperative pathological anatomy (APio) to determine if the removed specimen is an abnormal parathyroid.

Material and method

92 patients underwent CMI RG--HPP with PGC after the administration of a dose of 99 mTc-MIBI. The information provided by the PGC in the analysis of the excised specimens is qualitatively compared (capture yes/no) with the result of the intraoperative pathological anatomy (APio). The Gold standard is the definitive histology.

Results

120 excised pieces are evaluated with GGio and APio. There were 110 agreements (95TP and 15TN) and 10 disagreements (3FP and 7FN). Of the 120 lesions, 102 were parathyroid and 18 were non-parathyroid. There was good agreement between intraoperative scintigraphy imaging (GGio) and PA, 70.1% according to Cohen's Kappa index. The GGio presented the following values ​​of Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, Positive Likelihood Ratio, Negative Likelihood Ratio and Overall Value of the Test (93.1%, 83.3%, 96.9%, 68.2%, 5.59, 0.08 and 0.92 respectively).

Conclusion

GGio is a rapid and effective surgical aid technique to confirm/rule out the possible parathyroid nature of the lesions removed in PPH surgery, but it cannot replace histological study.

导言:原发性甲状旁腺功能亢进症(PPH)的根治性治疗方法是外科手术,如今可以通过微创手术(MIS)进行治疗,如果注射与甲状旁腺组织有亲和力的放射性药物,并能用伽马探测器探头或便携式伽马照相机(PGC)进行检测,还可以通过放射引导(RG)进行治疗。材料与方法:92名患者在接受了CMI RG--HPP手术后,注射了99 mTc-MIBI剂量的PGC。PGC在分析切除标本时提供的信息与术中病理解剖(APio)结果进行定性比较(捕获是/否)。结果:使用 GGio 和 APio 对 120 块切除标本进行评估。结果:用 GGio 和 APio 评估了 120 个切除病灶,结果一致的有 110 个(95 个 T P 和 15 个 TN),不一致的有 10 个(3 个 F P 和 7 个 F N)。在 120 例病变中,102 例为甲状旁腺,18 例为非甲状旁腺。根据科恩卡帕指数,术中闪烁成像(GGio)与 PA 的一致性很好,达到 70.1%。GGio的灵敏度、特异度、阳性预测值、阴性预测值、阳性似然比、阴性似然比和总测试值分别为93.1%、83.3%、96.9%、68.2%、5.59、0.08和0.92:GGio是一种快速有效的外科辅助技术,可用于确认/排除PPH手术中切除病灶可能具有的甲状旁腺性质,但它不能取代组织学研究。
{"title":"Comparison of intraoperative imaging with a portable gamma camera with extemporaneous histology in minimally invasive surgery for primary hyperparathyroidism","authors":"Abreu P. ,&nbsp;Guallart F. ,&nbsp;Siscar C. ,&nbsp;Navas M.A. ,&nbsp;Casas L. ,&nbsp;Montenegro F.","doi":"10.1016/j.remnie.2024.500030","DOIUrl":"10.1016/j.remnie.2024.500030","url":null,"abstract":"<div><h3>Introduction</h3><p>The curative treatment of primary hyperparathyroidism (PPH) is surgical and today it can be performed by minimally invasive surgery (MIS) and also be radioguided (RG) if a radiopharmaceutical with affinity for the parathyroid tissue that can be detected with gamma-detector probes or with a portable gamma camera (PGC) is injected.</p></div><div><h3>Aim</h3><p>The objective is to assess whether intraoperative scintigraphy (GGio) with PGC can replace intraoperative pathological anatomy (APio) to determine if the removed specimen is an abnormal parathyroid.</p></div><div><h3>Material and method</h3><p>92 patients underwent CMI RG--HPP with PGC after the administration of a dose of 99 mTc-MIBI. The information provided by the PGC in the analysis of the excised specimens is qualitatively compared (capture yes/no) with the result of the intraoperative pathological anatomy (APio). The Gold standard is the definitive histology.</p></div><div><h3>Results</h3><p>120 excised pieces are evaluated with GGio and APio. There were 110 agreements (95TP and 15TN) and 10 disagreements (3FP and 7FN). Of the 120 lesions, 102 were parathyroid and 18 were non-parathyroid. There was good agreement between intraoperative scintigraphy imaging (GGio) and PA, 70.1% according to Cohen's Kappa index. The GGio presented the following values ​​of Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, Positive Likelihood Ratio, Negative Likelihood Ratio and Overall Value of the Test (93.1%, 83.3%, 96.9%, 68.2%, 5.59, 0.08 and 0.92 respectively).</p></div><div><h3>Conclusion</h3><p>GGio is a rapid and effective surgical aid technique to confirm/rule out the possible parathyroid nature of the lesions removed in PPH surgery, but it cannot replace histological study.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500030"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revealing undetected axillary sentinel node in neoadjuvant chemotherapy treated breast cancer 揭示新辅助化疗乳腺癌患者未检测到的腋窝前哨结节
Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500024
{"title":"Revealing undetected axillary sentinel node in neoadjuvant chemotherapy treated breast cancer","authors":"","doi":"10.1016/j.remnie.2024.500024","DOIUrl":"10.1016/j.remnie.2024.500024","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 4","pages":"Article 500024"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141238205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the speciality future: challenges and opportunities in nuclear medicine 揭开专科未来的面纱:核医学的挑战与机遇。
Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500036
{"title":"Unveiling the speciality future: challenges and opportunities in nuclear medicine","authors":"","doi":"10.1016/j.remnie.2024.500036","DOIUrl":"10.1016/j.remnie.2024.500036","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 4","pages":"Article 500036"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reliability and readability analysis of ChatGPT-4 and Google Bard as a patient information source for the most commonly applied radionuclide treatments in cancer patients GPT-4 和 google bard 作为癌症患者最常用放射性核素治疗的患者信息来源的可靠性和可读性分析。
Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500021

Purpose

Searching for online health information is a popular approach employed by patients to enhance their knowledge for their diseases. Recently developed AI chatbots are probably the easiest way in this regard. The purpose of the study is to analyze the reliability and readability of AI chatbot responses in terms of the most commonly applied radionuclide treatments in cancer patients.

Methods

Basic patient questions, thirty about RAI, PRRT and TARE treatments and twenty-nine about PSMA-TRT, were asked one by one to GPT-4 and Bard on January 2024. The reliability and readability of the responses were assessed by using DISCERN scale, Flesch Reading Ease(FRE) and Flesch-Kincaid Reading Grade Level(FKRGL).

Results

The mean (SD) FKRGL scores for the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatmens were 14.57 (1.19), 14.65 (1.38), 14.25 (1.10), 14.38 (1.2) and 11.49 (1.59), 12.42 (1.71), 11.35 (1.80), 13.01 (1.97), respectively. In terms of readability the FRKGL scores of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were above the general public reading grade level. The mean (SD) DISCERN scores assesses by nuclear medicine phsician for the responses of GPT-4 and Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 47.86 (5.09), 48.48 (4.22), 46.76 (4.09), 48.33 (5.15) and 51.50 (5.64), 53.44 (5.42), 53 (6.36), 49.43 (5.32), respectively. Based on mean DISCERN scores, the reliability of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT, and TARE treatments ranged from fair to good. The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of GPT-4 about RAI, PSMA-TRT, PRRT and TARE treatments were 0.512(95% CI 0.296: 0.704), 0.695(95% CI 0.518: 0.829), 0.687(95% CI 0.511: 0.823) and 0.649 (95% CI 0.462: 0.798), respectively (p < 0.01). The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 0.753(95% CI 0.602: 0.863), 0.812(95% CI 0.686: 0.899), 0.804(95% CI 0.677: 0.894) and 0.671 (95% CI 0.489: 0.812), respectively (p < 0.01). The inter-rater reliability for the responses of Bard and GPT-4 about RAİ, PSMA-TRT, PRRT and TARE treatments were moderate to good. Further, consulting to the nuclear medicine physician was rarely emphasized both in GPT-4 and Google Bard and references were included in some responses of Google Bard, but there were no references in GPT-4.

Conclusion

Although the information provided by AI chatbots may be acceptable in medical terms, it can not be easy to read for the general public, which may prevent it from being understandable. Effective prompts using 'prompt engineering'

目的:搜索在线健康信息是患者常用的一种方法,以增强他们对疾病的了解。最近开发的人工智能聊天机器人可能是这方面最简单的方法。本研究的目的是分析人工智能聊天机器人在癌症患者最常用的放射性核素治疗方面的回答的可靠性和可读性:方法:在 2024 年 1 月向 GPT-4 和 Bard 逐一询问了患者的基本问题,其中 30 个是关于 RAI、PRRT 和 TARE 治疗的,29 个是关于 PSMA-TRT 的。采用 DISCERN 量表、Flesch Reading Ease(FRE)和 Flesch-Kincaid Reading Grade Level(FKRGL)对回答的可靠性和可读性进行了评估:GPT-4和谷歌巴德关于RAI、PSMA-TRT、PRRT和TARE治疗的平均(标清)FKRGL分数分别为14.57(1.19)、14.65(1.38)、14.25(1.10)、14.38(1.2)和11.49(1.59)、12.42(1.71)、11.35(1.80)、13.01(1.97)。就可读性而言,关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的 GPT-4 和 Google Bard 的 FRKGL 分数高于一般公众的阅读水平。核医学医生对 GPT-4 和谷歌巴德关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答进行评估后得出的 DISCERN 平均分(标度)分别为 47.86(5.09)、48.48(4.22)、46.76(4.09)、48.33(5.15)和 51.50(5.64)、53.44(5.42)、53(6.36)、49.43(5.32)。根据 DISCERN 平均得分,GPT-4 和 Google Bard 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答的可靠性从一般到良好不等。由 GPT-4、谷歌巴德和核医学医生对 GPT-4 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答所评估的 DISCERN 分数的评分者间可靠性相关系数分别为 0.512(95% CI 0.296:0.704)、0.695(95% CI 0.518:0.829)、0.687(95% CI 0.511:0.823)和 0.649(95% CI 0.462:0.798)(P 结论:GPT-4、谷歌巴德和核医学医生对 GPT-4 的回答所评估的 DISCERN 分数的评分者间可靠性相关系数分别为 0.512(95% CI 0.296:0.704)、0.695(95% CI 0.518:0.829)、0.687(95% CI 0.511:0.823)和 0.649(95% CI 0.462:0.798):虽然人工智能聊天机器人提供的信息在医学术语上可以接受,但对于普通大众来说却不容易阅读,这可能会妨碍其理解。使用 "提示工程 "进行有效提示,可以以更易于理解的方式完善回复。由于放射性核素治疗是核医学专业知识的特定内容,因此需要在回答中说明核医学医生是顾问,以指导患者和护理人员获得准确的医疗建议。就患者和护理人员寻求信息的信心和满意度而言,参考意义重大。
{"title":"Reliability and readability analysis of ChatGPT-4 and Google Bard as a patient information source for the most commonly applied radionuclide treatments in cancer patients","authors":"","doi":"10.1016/j.remnie.2024.500021","DOIUrl":"10.1016/j.remnie.2024.500021","url":null,"abstract":"<div><h3>Purpose</h3><p>Searching for online health information is a popular approach employed by patients to enhance their knowledge for their diseases. Recently developed AI chatbots are probably the easiest way in this regard. The purpose of the study is to analyze the reliability and readability of AI chatbot responses in terms of the most commonly applied radionuclide treatments in cancer patients.</p></div><div><h3>Methods</h3><p>Basic patient questions, thirty about RAI, PRRT and TARE treatments and twenty-nine about PSMA-TRT, were asked one by one to GPT-4 and Bard on January 2024. The reliability and readability of the responses were assessed by using DISCERN scale, Flesch Reading Ease(FRE) and Flesch-Kincaid Reading Grade Level(FKRGL).</p></div><div><h3>Results</h3><p><span><span>The mean (SD) FKRGL scores for the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatmens were 14.57 (1.19), 14.65 (1.38), 14.25 (1.10), 14.38 (1.2) and 11.49 (1.59), 12.42 (1.71), 11.35 (1.80), 13.01 (1.97), respectively. In terms of readability the FRKGL scores of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were above the general public reading grade level. The mean (SD) DISCERN scores assesses by nuclear medicine phsician for the responses of GPT-4 and Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 47.86 (5.09), 48.48 (4.22), 46.76 (4.09), 48.33 (5.15) and 51.50 (5.64), 53.44 (5.42), 53 (6.36), 49.43 (5.32), respectively. Based on mean DISCERN scores, the reliability of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT, and TARE treatments ranged from fair to good. The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and </span>nuclear medicine physician for the responses of GPT-4 about RAI, PSMA-TRT, PRRT and TARE treatments were 0.512(95% CI 0.296: 0.704), 0.695(95% CI 0.518: 0.829), 0.687(95% CI 0.511: 0.823) and 0.649 (95% CI 0.462: 0.798), respectively (</span><em>p</em> &lt; 0.01). The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 0.753(95% CI 0.602: 0.863), 0.812(95% CI 0.686: 0.899), 0.804(95% CI 0.677: 0.894) and 0.671 (95% CI 0.489: 0.812), respectively (<em>p</em> &lt; 0.01). The inter-rater reliability for the responses of Bard and GPT-4 about RAİ, PSMA-TRT, PRRT and TARE treatments were moderate to good. Further, consulting to the nuclear medicine physician was rarely emphasized both in GPT-4 and Google Bard and references were included in some responses of Google Bard, but there were no references in GPT-4.</p></div><div><h3>Conclusion</h3><p>Although the information provided by AI chatbots may be acceptable in medical terms, it can not be easy to read for the general public, which may prevent it from being understandable. Effective prompts using 'prompt engineering'","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 4","pages":"Article 500021"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostatic rhabdomyosarcoma in a 6 years old patient evaluated by [18F]FDG PET/CT 用[18F]FDG PET/CT 评估一名 6 岁患者的前列腺横纹肌肉瘤。
Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500016
{"title":"Prostatic rhabdomyosarcoma in a 6 years old patient evaluated by [18F]FDG PET/CT","authors":"","doi":"10.1016/j.remnie.2024.500016","DOIUrl":"10.1016/j.remnie.2024.500016","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 4","pages":"Article 500016"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141187150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de medicina nuclear e imagen molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1